{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:41:29Z","timestamp":1789663289356,"version":"4.0.1"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_almed-2025-0144_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Alpha-fetoprotein L3 (AFP-L3\u202f%) and protein induced by vitamin K absence-II (PIVKA-II) are used in diagnostic scores such as GAAD, GALAD, and ASAP for hepatocellular carcinoma (HCC) detection. Advanced liver fibrosis (ALF) is diagnosable by the liver fibrosis index and could be combined with these blood biomarkers for better HCC detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_almed-2025-0144_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study developed an analytical framework to address the role of GAAD, GALAD, and ASAP in ALF patients as a risk score to predict HCC. By analyzing data from 21 HCC and 30 ALF patients, this analysis assessed the diagnostic accuracy of individual biomarkers, ASAP, GAAD, and GALAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_almed-2025-0144_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GAAD slightly outperformed AFP (sensitivity: 76.2\u202f%, specificity: 88.5\u202f%). The combination of AFP and PIVKA-II also surpassed AFP alone. PIVKA-II and AFP-L3 showed the worst performance for identifying\u00a0HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_almed-2025-0144_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GAAD and ASAP showed comparable or slightly superior performance to AFP, suggesting potential for screening strategies that should be confirmed in larger studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/almed-2025-0144","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:56:37Z","timestamp":1768391797000},"page":"43-51","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of diagnostic performance of GAAD, GALAD, and ASAP scores for detecting hepatocellular carcinoma in advanced liver fibrosis patients"],"prefix":"10.1515","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2517-6152","authenticated-orcid":false,"given":"Alberto","family":"Izquierdo-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry , Virgen del Roc\u00edo University Hospital , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Rojas","sequence":"additional","affiliation":[{"name":"SeLiver Group at Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital\/CSIC\/University of Seville , Seville , Spain"},{"name":"CIBERehd, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6313-4191","authenticated-orcid":false,"given":"Ricardo","family":"Rubio-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry , Virgen del Roc\u00edo University Hospital , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Dominguez-Pascual","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry , Virgen del Roc\u00edo University Hospital , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[{"name":"SeLiver Group at Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital\/CSIC\/University of Seville , Seville , Spain"},{"name":"CIBERehd, Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Facultad de Biolog\u00eda, Departamento de Fisiolog\u00eda , Universidad de Sevilla , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fatela-Cantillo","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry , Virgen del Roc\u00edo University Hospital , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"2026031715433068227_j_almed-2025-0144_ref_001","doi-asserted-by":"crossref","unstructured":"Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"2026031715433068227_j_almed-2025-0144_ref_002","doi-asserted-by":"crossref","unstructured":"Eslam, M, Newsome, PN, Sarin, SK, Anstee, QM, Targher, G, Romero-Gomez, M, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J\u00a0Hepatol 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"2026031715433068227_j_almed-2025-0144_ref_003","doi-asserted-by":"crossref","unstructured":"Vilar-Gomez, E, Calzadilla-Bertot, L, Wai-Sun, V, Castellanos, M, Aller-de la Fuente, R, Metwally, M, et al.. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 2018;155:443\u201357. https:\/\/doi.org\/10.1053\/j.gastro.2018.04.034.","DOI":"10.1053\/j.gastro.2018.04.034"},{"key":"2026031715433068227_j_almed-2025-0144_ref_004","doi-asserted-by":"crossref","unstructured":"Roehlen, N, Crouchet, E, Baumert, TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 2020;9:875. https:\/\/doi.org\/10.3390\/cells9040875.","DOI":"10.3390\/cells9040875"},{"key":"2026031715433068227_j_almed-2025-0144_ref_005","doi-asserted-by":"crossref","unstructured":"Forner, A, Llovet, JM, Mazzaferro, V, Piscaglia, F, Raoul, JL. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J\u00a0Hepatol 2018;69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"2026031715433068227_j_almed-2025-0144_ref_006","doi-asserted-by":"crossref","unstructured":"Kjaergaard, M, Lindvig, KP, Thorhauge, KH, Andersen, P, Hansen, JK, Kastrup, N, et al.. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J\u00a0Hepatol 2023;79:277\u201386. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.002.","DOI":"10.1016\/j.jhep.2023.04.002"},{"key":"2026031715433068227_j_almed-2025-0144_ref_007","doi-asserted-by":"crossref","unstructured":"Singal, AG, Llovet, JM, Yarchoan, M, Mehta, N, Heimbach, JK, Dawson, LA, et al.. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatol Baltim Md 2023;78:1922\u201365. https:\/\/doi.org\/10.1097\/hep.0000000000000466.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"2026031715433068227_j_almed-2025-0144_ref_008","doi-asserted-by":"crossref","unstructured":"Loomba, R, Lim, JK, Patton, H, El-Serag, HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 2020;158:1822\u201330. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.053.","DOI":"10.1053\/j.gastro.2019.12.053"},{"key":"2026031715433068227_j_almed-2025-0144_ref_009","doi-asserted-by":"crossref","unstructured":"Tzartzeva, K, Obi, J, Rich, NE, Parikh, ND, Marrero, JA, Yopp, A, et al.. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706\u201318. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.064.","DOI":"10.1053\/j.gastro.2018.01.064"},{"key":"2026031715433068227_j_almed-2025-0144_ref_010","doi-asserted-by":"crossref","unstructured":"Shahini, E, Pasculli, G, Solimando, AG, Tiribelli, C, Cozzolongo, R, Giannelli, G. Updating the clinical application of blood biomarkers and their algorithms in the diagnosis and surveillance of hepatocellular carcinoma: a critical review. Int J Mol Sci 2023;24:4286. https:\/\/doi.org\/10.3390\/ijms24054286.","DOI":"10.3390\/ijms24054286"},{"key":"2026031715433068227_j_almed-2025-0144_ref_011","doi-asserted-by":"crossref","unstructured":"Wang, X, Zhang, Y, Yang, N, He, H, Tao, X, Kou, C, et al.. Evaluation of the combined application of AFP, AFP-L3\u202f%, and DCP for hepatocellular carcinoma diagnosis: a meta-analysis. Biomed Res Int 2020:5087643. https:\/\/doi.org\/10.1155\/2020\/5087643.","DOI":"10.1155\/2020\/5087643"},{"key":"2026031715433068227_j_almed-2025-0144_ref_012","doi-asserted-by":"crossref","unstructured":"Cagnin, S, Donghia, R, Martini, A, Pesole, PL, Coletta, S, Shahini, E, et al.. Galad score as a prognostic marker for patients with hepatocellular carcinoma. Int J Mol Sci 2023;24:16485. https:\/\/doi.org\/10.3390\/ijms242216485.","DOI":"10.3390\/ijms242216485"},{"key":"2026031715433068227_j_almed-2025-0144_ref_013","doi-asserted-by":"crossref","unstructured":"Guan, MC, Zhang, SY, Li, N, Ding, Q, Fu, TT, Zhang, GX, et al.. The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases: a systematic review and meta-analysis. J\u00a0Clin Med 2023;12:949. https:\/\/doi.org\/10.3390\/jcm12030949.","DOI":"10.3390\/jcm12030949"},{"key":"2026031715433068227_j_almed-2025-0144_ref_014","doi-asserted-by":"crossref","unstructured":"Ampuero, J, Aller, R, Gallego-Dur\u00e1n, R, Crespo, J, Calleja, JL, Garc\u00eda-Monz\u00f3n, C, et al.. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. J\u00a0Hepatol 2020;73:17\u201325.","DOI":"10.1016\/j.jhep.2020.02.028"},{"key":"2026031715433068227_j_almed-2025-0144_ref_015","doi-asserted-by":"crossref","unstructured":"Piratvisuth, T, Tanwandee, T, Thongsawat, S, Sukeepaisarnjaroen, W, Esteban, JI, Bes, M, et al.. Multimarker panels for detection of early stage hepatocellular carcinoma: a prospective, multicenter, case-control study. Hepatol Commun 2022;6:679\u201391. https:\/\/doi.org\/10.1002\/hep4.1847.","DOI":"10.1002\/hep4.1847"},{"key":"2026031715433068227_j_almed-2025-0144_ref_016","doi-asserted-by":"crossref","unstructured":"Yang, T, Xing, H, Wang, G, Liu, M, Yan, C, Li, H, et al.. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin Chem 2019;65:1543\u201353. https:\/\/doi.org\/10.1373\/clinchem.2019.308965.","DOI":"10.1373\/clinchem.2019.308965"},{"key":"2026031715433068227_j_almed-2025-0144_ref_017","doi-asserted-by":"crossref","unstructured":"Kim, DY, Toan, BN, Tan, CK, Hasan, I, Setiawan, L, Yu, ML, et al.. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol 2023;29:277\u201392. https:\/\/doi.org\/10.3350\/cmh.2022.0212.","DOI":"10.3350\/cmh.2022.0212"},{"key":"2026031715433068227_j_almed-2025-0144_ref_018","doi-asserted-by":"crossref","unstructured":"Liu, SY, Li, C, Sun, LY, Guan, MC, Gu, LH, Yin, DX, et al.. ASAP score versus GALAD score for detection of hepatitis C-related hepatocellular carcinoma: a multicenter case-control analysis. Front Oncol 2022;12:1018396. https:\/\/doi.org\/10.3389\/fonc.2022.1018396.","DOI":"10.3389\/fonc.2022.1018396"},{"key":"2026031715433068227_j_almed-2025-0144_ref_019","doi-asserted-by":"crossref","unstructured":"Piratvisuth, T, Hou, J, Tanwandee, T, Berg, T, Vogel, A, Trojan, J, et al.. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies. Hepatol Commun 2023;7. https:\/\/doi.org\/10.1097\/hc9.0000000000000317.","DOI":"10.1097\/HC9.0000000000000317"},{"key":"2026031715433068227_j_almed-2025-0144_ref_020","doi-asserted-by":"crossref","unstructured":"Notarpaolo, A, Layese, R, Magistri, P, Gambato, M, Colledan, M, Magini, G, et al.. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J\u00a0Hepatol 2017;66:552\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2016.10.038.","DOI":"10.1016\/j.jhep.2016.10.038"},{"key":"2026031715433068227_j_almed-2025-0144_ref_021","doi-asserted-by":"crossref","unstructured":"Si, YQ, Wang, XQ, Fan, G, Wang, CY, Zheng, YW, Song, X, et al.. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation. Infect Agents Cancer 2020;15:70. https:\/\/doi.org\/10.1186\/s13027-020-00337-0.","DOI":"10.1186\/s13027-020-00337-0"},{"key":"2026031715433068227_j_almed-2025-0144_ref_022","doi-asserted-by":"crossref","unstructured":"Chan, HLY, Hu, Y, Malinowsky, K, Madin, K, Kroeniger, K, Hou, J, et al.. Prospective appraisal of clinical diagnostic algorithms for hepatocellular carcinoma surveillance in Chinese patients with chronic hepatitis B infection. Sci Rep 2024;14:28996. https:\/\/doi.org\/10.1038\/s41598-024-80257-w.","DOI":"10.1038\/s41598-024-80257-w"},{"key":"2026031715433068227_j_almed-2025-0144_ref_023","doi-asserted-by":"crossref","unstructured":"Liu, S, Sun, L, Yao, L, Zhu, H, Diao, Y, Wang, M, et al.. Diagnostic performance of AFP, AFP-L3, or PIVKA-II for hepatitis C virus-associated hepatocellular carcinoma: a multicenter analysis. J\u00a0Clin Med 2022;11:5075. https:\/\/doi.org\/10.3390\/jcm11175075.","DOI":"10.3390\/jcm11175075"},{"key":"2026031715433068227_j_almed-2025-0144_ref_024","doi-asserted-by":"crossref","unstructured":"Singal, AG, Tayob, N, Mehta, A, Marrero, JA, El\u2010Serag, H, Jin, Q, et al.. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 2022;75:541\u20139. https:\/\/doi.org\/10.1002\/hep.32185.","DOI":"10.1002\/hep.32185"},{"key":"2026031715433068227_j_almed-2025-0144_ref_026","doi-asserted-by":"crossref","unstructured":"Durazo, F, Blatt, LM, Corey, W, Lin, J, Han, S, Saab, S, et al.. Des\u2010\u03b3\u2010carboxyprothrombin, \u03b1\u2010fetoprotein and AFP\u2010L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J\u00a0Gastroenterol Hepatol 2008;23:1541\u20138. https:\/\/doi.org\/10.1111\/j.1440-1746.2008.05395.x.","DOI":"10.1111\/j.1440-1746.2008.05395.x"},{"key":"2026031715433068227_j_almed-2025-0144_ref_027","doi-asserted-by":"crossref","unstructured":"Liu, S, Sun, L-Y, Yao, L, Zhu, H, Diao, Y, Wang, M, et al.. Diagnostic performance of AFP, AFP-L3, or PIVKA-II for hepatitis C virus-associated hepatocellular carcinoma: a multicenter analysis. Stomatology 2022;11:5075. https:\/\/doi.org\/10.3390\/jcm11175075.","DOI":"10.3390\/jcm11175075"}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0144\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:59:42Z","timestamp":1773763182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0144\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2026,3,16]]}},"alternative-id":["10.1515\/almed-2025-0144"],"URL":"https:\/\/doi.org\/10.1515\/almed-2025-0144","relation":{},"ISSN":["2628-491X"],"issn-type":[{"value":"2628-491X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}